International Actions Watch

Mentioned 1× · first seen 12-jul-2026 · last seen 12-jul-2026

Section 301 Investigation — Germany Pharmaceutical Reimbursement

Current understanding

The Office of the U.S. Trade Representative has initiated a Section 301 investigation into Germany’s practices regarding reimbursement for innovative pharmaceutical products, alleging persistent underpayment. USTR has scheduled a public hearing and opened a comment period; the investigation is at the initiation stage, with no determination or remedial action (such as tariffs) yet imposed.

Evidence log

Open questions

Contributing findings

ustr-trade trade action

Initiation of Section 301 Investigation; Hearing; and Request for Public Comments: Germany's Persistent Underpayment for Innovative Pharmaceutical Products

24-jun-2026 novelty 3 per-area 3 introduces

Ask about this page

Replies are grounded in this page's wiki content and the findings linked above. Citations to findings render as [F123] links.

Stages other doctrine treaty transmitted treaty committee aid award arms sale trade action sanction executive order executive agreement treaty advice consent treaty in force

Subscribe: calendar of upcoming dates · deadlines feed · all new records